Combined screening with PLGF (Delfia)+ NIPT + Hemoglobinopathy by HPLC

Combined Screening with PLGF (DELFIA) + NIPT + Hemoglobinopathy by HPLC

A comprehensive prenatal screening package for maternal and fetal health assessment.

Why is this test done?

This advanced screening combines first-trimester risk assessment, fetal genetic screening, and hemoglobinopathy evaluation to provide a detailed overview of pregnancy health.

What does it include?

• PLGF (Placental Growth Factor) by DELFIA – Helps assess the risk of preeclampsia and supports placental health evaluation.
• Combined First Trimester Screening – Estimates the risk of chromosomal abnormalities such as Down syndrome (Trisomy 21), Trisomy 18, and Trisomy 13.
• NIPT (Non-Invasive Prenatal Testing) – Screens fetal DNA in maternal blood for common chromosomal abnormalities with high accuracy.
• Hemoglobinopathy Screening by HPLC – Detects inherited blood disorders such as sickle cell disease and thalassemia.

Who should consider this test?

• Pregnant women during the first trimester (11–13+6 weeks).
• Women aged 35 years or older.
• Those with a family history of genetic or blood disorders.
• Couples seeking comprehensive prenatal screening.
• Pregnancies requiring enhanced fetal risk assessment.

Sample Required

• Maternal blood sample.

Benefits

• Early assessment of fetal chromosomal abnormalities.
• Evaluates the risk of preeclampsia.
• Detects inherited hemoglobin disorders.
• Non-invasive and safe for both mother and baby.
• Supports informed pregnancy management and timely medical decisions.

Note: This is a screening test, not a diagnostic test. Any high-risk result should be confirmed with appropriate diagnostic procedures as advised by your healthcare provider.

#Dermafact #gynofact #PrenatalScreening #NIPT #PLGF #CombinedScreening #Hemoglobinopathy #HPLC #PregnancyCare #FetalHealth #GeneticScreening #AdvancedDiagnostics #AdvancedBioCareLaboratories